REVEALing the effect of CETP inhibition in cardiovascular disease

被引：39

作者：

Holmes, Michael V. ^{[1
,2
,3
,4
,5
]}

Smith, George Davey ^{[6
,7
,8
]}

机构：

[1] Univ Oxford, Med Res Council, Populat Hlth Res Unit, Oxford OX3 7LF, England

[2] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Roosevelt Dr, Oxford OX3 7LF, England

[3] Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit CTSU, Roosevelt Dr, Oxford OX3 7LF, England

[4] Oxford Univ Hosp, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Old Rd, Oxford OX3 7LE, England

[5] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England

[6] MRC, Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England

[7] Natl Inst Hlth Res, Bristol Biomed Res Ctr, Oakfield House, Bristol BS8 2BN, Avon, England

[8] Univ Bristol, Sch Social & Community Med, Barley House, Bristol BS8 2BN, Avon, England

来源：

NATURE REVIEWS CARDIOLOGY | 2017年 / 14卷 / 11期

基金：

英国医学研究理事会;

关键词：

CORONARY-ARTERY-DISEASE; HIGH-RISK;

D O I：

10.1038/nrcardio.2017.156

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.

引用

页码：635 / 636

页数：2

共 50 条

[1] CETP inhibition and HDL: what is the trial REVEALing?
Badimon, Lina
CARDIOVASCULAR RESEARCH, 2018, 114 (02) : E15 - E16
[2] Effect of interleukin 1β inhibition in cardiovascular disease
Qamar, Arman
Rader, Daniel J.
CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 548 - 553
[3] CETP inhibition in perspective
Stock, Jane
ATHEROSCLEROSIS, 2012, 220 (02) : 325 - 328
[4] Safety of CETP inhibition
Duivenvoorden, Raphael
Fayad, Zahi A.
CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 518 - 524
[5] Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
Nicholls, Stephen J.
Ray, Kausik K.
Nelson, Adam J.
Kastelein, John J. P.
CURRENT OPINION IN LIPIDOLOGY, 2022, 33 (06) : 319 - 325
[6] CETP inhibition, statins and diabetes
Barter, Philip J.
Cochran, Blake J.
Rye, Kerry-Anne
ATHEROSCLEROSIS, 2018, 278 : 143 - 146
[7] Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, Trine Holm
Frikke-Schmidt, Ruth
Schou, Jesper
Nordestgaard, Borge G.
Tybjaerg-Hansen, Anne
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (20) : 2041 - 2048
[8] Dalcetrapib: turning the tide for CETP inhibition?
Stroes, Erik S. G.
van Wijk, Diederik F.
LANCET, 2011, 378 (9802) : 1529 - 1530
[9] Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
Menon, Venu
Kumar, Anirudh
Patel, Divyang R.
St John, Julie
Riesmeyer, Jeffrey
Weerakkody, Govinda
Ruotolo, Giacomo
Wolski, Kathy E.
McErlean, Ellen
Cremer, Paul C.
Nicholls, Stephen J.
Lincoff, A. Michael
Nissen, Steven E.
BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
[10] Multi-omics approaches for revealing the complexity of cardiovascular disease
Doran, Stephen
Arif, Muhammad
Lam, Simon
Bayraktar, Abdulahad
Turkez, Hasan
Uhlen, Mathias
Boren, Jan
Mardinoglu, Adil
BRIEFINGS IN BIOINFORMATICS, 2021, 22 (05)

← 1 2 3 4 5 →